Investor Presentaiton
We will continue to provide attractive cash returns despite investments
in commercial activities and the Atos Medical and Kerecis acquisitions
Coloplast cash distribution to investors
Highlights
Dividends paid out in the year (DKKm) (1) Share buy-back (DKKm)
Pay-out ratio (%) (2)
91
88
86
84
84
81
77
4,541
4,330
4,112
3,788
3,898
3,364
3,150
500
15/16
500
16/17
500
17/18
500
18/19
500
500
19/20
20/21
500
21/22
88
80
60
60
Long-term
1) Dividends paid out in the year are the actual cash payments of which the majority relates to dividend proposed in the previous financial year.
2) Pay-out ratio calculated as dividend proposed in the financial year/net profit for the financial year. Pay-out ratio for 2021/22 is before special items related to Mesh litigation
and Atos Medical acquisition. 2020/21, 2018/19 and 2015/16 is before special items related to Mesh litigation. After special items, the pay-out ratio for 21/22 was 90%
43
•
•
Coloplast returns excess liquidity to shareholders in
the form of dividends and share buy-backs
Dividend is paid twice a year - after the half-year
and full-year financial reporting
Total dividend of DKK 20.00 per share for 2021/22
compared to DKK 19.00 per share for 2020/21
H1 2022/23 interim dividend of DKK 5.00 per
share, and a total interim dividend of DKK 1,062
million
•
•
The share buy-back programme serves to hedge
employee share options
A new share buy-back program will not be initiated
in FY 2022/23 as treasury shares are sufficient to
hedge the outstanding employee share options
ColoplastView entire presentation